|
FDA Reviewers Raise Toxicity Concerns With Onyx’s Multiple Myeloma Drug
The heart, lung and liver toxicities associated with Onyx Pharmaceuticals’ multiple myeloma treatment Kyprolis could mean that the drug is not superior to other multiple myeloma drugs on the market, FDA reviewers say in draft documents released before Wednesday’s meeting of the Oncologic Drugs Advisory Committee.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives